The eleventh international childhood acute lymphoblastic leukemia workshop report: Ponte di Legno, Italy, 6-7 may 2009

Leukemia

Volumn 23, Issue 12, 2009, Pages 2318-2324

  Biondi, A ^a   Baruchel, A ^b   Hunger, S ^c   Masera, G ^a   Schmiegelow, K ^d   Schrappe, M ^e   Pui, C H ^f  

^a SAN GERARDO HOSPITAL   (Italy)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITY OF COLORADO   (United States)

^d Rigshospitalet   (Denmark)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

19) ALL, dic(9; 20) ALL; acute lymphoblastic leukemia; Down's syndrome ALL; leukemia induction failure; Philadelphia chromosome positive ALL; t(1

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; CONFERENCE PAPER; DOWN SYNDROME; DRUG DELIVERY SYSTEM; EDUCATION; GENETICS; HUMAN; INTERNATIONAL COOPERATION; ITALY; METHODOLOGY; MORTALITY;

DOWN SYNDROME; DRUG DELIVERY SYSTEMS; EDUCATION; HUMANS; INTERNATIONAL COOPERATION; ITALY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 74049094433     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.211     Document Type: Conference Paper

References (37)

1. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M et al. German-Austrian-Swiss ALL-BFM Study Group. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489.
2. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC et al. Treating childhood acute lymphoblastic leukemia without prophylactic cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
3. Prucker C, Attarbaschi A, Peters C, Dworzak MN, Pötschger U, Urban C et al. Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Mü nster study group. Leukemia 2009; 23: 1264-1269.
4. Oudot C, Auclerc MF, Levy V, Porcher R, Piguet C, Perel Y et al. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol 2008; 26: 1496-1503.
5. Aricó M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006. (Pubitemid 30180646)
6. LaRussa P, Steinberg S, Gershon AA. Varicella vaccine for immunocompromised children: results of collaborative studies in the United States and Canada. J Infect Dis 1996; 174 (Suppl 3): S320-S323. (Pubitemid 26357215)
7. Schrauder A, Henke-Gendo C, Seidemann K, Sasse M, Cario G, Moericke A et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet 2007; 369: 1232. (Pubitemid 46527878)
8. Salzer WL, Devidas M, Carroll W, Winick N, Pullen J, Hunger SP et al. Long-term results of the Pediatric Oncology Group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the Children's Oncology Group. Leukemia (in press).
9. Jeha S, Pei D, Raimondi SC, Onciu M, Campana D, Cheng C et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009; 23: 1406-1409.
10. Garg R, Kantarjian H, Thomas D, Faderl S, Ravandi F, Lovshe D et al. Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy. Cancer 2009; 115: 2147-2154.
11. Inukai T, Hirose K, Inaba T, Kurosawa H, Hama A, Inada H et al. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia 2007; 21: 288-296. (Pubitemid 46158122)
12. Forestier E, Gauffin F, Andersen MK, Autio K, Borgström G, Golovleva I et al. Clinical and cytogenetic features of pediatric dic(9;20)(p13.2;q11.2)- positive B-cell precursor acute lymphoblastic leukemias: a Nordic series of 24 cases and review of the literature. Genes Chromosomes Cancer 2008; 47: 149-158.
13. Lönnerholm G, Nordgren A, Frost BM, Jonsson OG, Kanerva J, Nygaard R et al. Dic(9;20)(p13;q11) in childhood acute lymphoblastic leukaemia is related to low cellular resistance to asparaginase, cytarabine and corticosteroids. Leukemia 2009; 23: 209-212.
14. Soulier J, Trakhtenbrot L, Najfeld V, Lipton JM, Mathew S, Avet-Loiseau H et al. Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: an emerging molecular cytogenetic subgroup. Leukemia 2003; 17: 1679-1682. (Pubitemid 36986978)
15. Harewood L, Robinson H, Harris R, Al-Obaidi MJ, Jalali GR, Martineau M et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia 2003; 17: 547-553. (Pubitemid 36395648)
16. Moorman AV, Richards SM, Robinson HM, Strefford JC, Gibson BE, Kinsey SE et al. Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21. (iAMP21). Blood 2007; 109: 2327-2330. (Pubitemid 46425871)
17. Attarbaschi A, Mann G, Panzer-Grümayer R, Rö ttgers S, Steiner M, König M et al. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials. J Clin Oncol 2008; 26: 3046-3050.
18. Strefford JC, van Delft FW, Robinson HM, Worley H, Yiannikouris O, Selzer R et al. Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21. Proc Natl Acad Sci USA 2006; 103: 8167-8172. (Pubitemid 43801070)
19. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32: 148-152. (Pubitemid 34977210)
20. Malinge S, Ben-Abdelali R, Settegrana C, Radford-Weiss I, Debre M, Beldjord K et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007; 109: 2202-2204. (Pubitemid 46348223)
21. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008; 372: 1484-1492.
22. Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009; 113: 646-648.
23. Gaikwad A, Rye CL, Devidas M, Heerema NA, Carroll AJ, Izraeli S et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009; 144: 930-932.
24. Buitenkamp T, Danen-van Oorschot AA, Van Den Heuvel-Eibrink M, van Wering E, Pieters R, Zwaan CM. The prognostic value of JAK2 exon 16 mutations in children with down syndrome and acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts) 2008; 112: 1518.
25. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106: 9414-9418.
26. Schmiegelow K, Al-Modhwahi I, Andersen MK, Behrendtz M, Forestier E, Hasle H et al. Nordic Society for Paediatric Haematology and Oncology. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood 2009; 113: 6077-6084.
27. Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S et al. International BFM Study Group (I-BFM-SG). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771-782.
28. Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P et al. AIEOP-BFM-FCM-MRD-Study Group. Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia 2009; 23: 528-534.
29. Van der Velden VHJ, Corral L, Valsecchi MG, Jansen MWJC, De Lorenzo P, Cazzaniga G et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009; 23: 1073-1079.
30. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429: 464-468. (Pubitemid 38715141)
31. Yang J, Cheng C, Yang W, Pei D, Cao X, Fan Y et al. Genome-wide interrogation of germline genetic variations associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009; 301: 393-403.
32. Peters EJ, McLeod HL. Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants. Pharmacogenomics 2008; 9: 1573-1577.
33. Schmiegelow K, Forestier E, Kristinsson J, Söderhä ll S, Vettenranta K, Weinshilboum R et al. Nordic Society of Paediatric Haematology and Oncology. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Leukemia 2009; 23: 557-564.
34. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M et al. Improved early event free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group Study. J Clin Oncol [E-pub ahead of print 5 October 2009].
35. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106: 9414-9418.
36. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LAA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
37. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10: 125-134.